Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 15/20 | 0.47 |
| ▸ | AXL | P30530 | 11/20 | 0.47 |
| ▸ | MET | P08581 | 2/20 | 0.47 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
| ▸ | PTGES | O14684 | 3/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2402509 | 0.99 | MERTK (0.46) | MERTKAXLMETTYRO3P2RX7 | |
| SCHEMBL6411128 | 0.86 | MERTK (0.44) | MERTKAXLMETTYRO3P2RX7 | |
| SCHEMBL2401835 | 0.84 | MERTK (0.42) | MERTKAXLMETTYRO3P2RX7 | |
| SCHEMBL2401521 | 0.83 | GPR119 (0.48) | MERTKAXLMETTYRO3P2RX7 | |
| SCHEMBL2402565 | 0.82 | MERTK (0.42) | MERTKAXLMETTYRO3P2RX7 | |
| SCHEMBL7035709 | 0.82 | MERTK (0.42) | MERTKAXLMETTYRO3P2RX7 | |
| SCHEMBL6409298 | 0.82 | MERTK (0.42) | MERTKAXLMETTYRO3P2RX7 | |
| SCHEMBL2401891 | 0.80 | MEN1 (0.42) | MERTKAXLMETTYRO3P2RX7 | |
| SCHEMBL2400825 | 0.80 | POLB (0.41) | MERTKAXLMETTYRO3P2RX7 | |
| SCHEMBL2579252 | 0.80 | ALDH1A1 (0.43) | MERTKAXLMETTYRO3P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048890-B2 | Analgesics; neuropathic pain; headaches; muscle relaxants; incontence; tinnitus; diarrhea; antiarrhythmia agents; antiischemic agents; antiinflammatory agents; antiulcer agents; antidepressants; antiepileptic agents | GRUENENTHAL GMBH (DE) | 2011-11-01 | — | — | US | disclosed |
| US-20110224172-A1 | Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods | GRUENENTHAL GMBH (DE) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224172-A1 | Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods | SULT1E1, DECR1, CYP8B1 | MERTK 1544/4885AXL 1732/4885MET 4101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.